A 52-year-old man with type 2 diabetes mellitus (HbA1c 9.2%) presents with blurred vision for 2 weeks. Fundoscopy reveals multiple dot-blot hemorrhages, hard exudates in a circinate pattern around the macula, and microaneurysms in all four quadrants. Visual acuity is 6/9 in both eyes. Optical coherence tomography (OCT) shows central macular thickness of 285 µm with intraretinal cystoid spaces. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **nonproliferative diabetic retinopathy (NPDR) with diabetic macular edema (DME)**. The key findings are: - Microaneurysms, dot-blot hemorrhages, hard exudates (NPDR features) - Circinate exudates around macula (DME indicator) - OCT-confirmed macular edema (285 µm; normal <250 µm) - Relatively preserved vision (6/9) ## Management Algorithm for DME with NPDR ```mermaid flowchart TD A[NPDR with DME]:::outcome --> B{Macular edema severity?}:::decision B -->|Mild/Moderate| C[Anti-VEGF first-line]:::action B -->|Severe| D[Anti-VEGF + Laser]:::action C --> E[Intravitreal bevacizumab/aflibercept]:::action E --> F[Repeat injections every 4 weeks]:::action F --> G[Add laser if inadequate response]:::action D --> H[Anti-VEGF + Macular laser]:::action H --> I[Combination therapy]:::action ``` ## Key Point: **Anti-VEGF is now first-line for DME in NPDR**, even without proliferative disease. This patient's vision is still relatively good (6/9), making anti-VEGF the optimal choice to prevent further vision loss and reduce macular thickness. ## High-Yield Facts: - **DRCR.net Protocol T (2015)**: Anti-VEGF agents (bevacizumab, aflibercept, ranibizumab) are superior to laser monotherapy for DME with NPDR - Laser photocoagulation is reserved for: - Inadequate response to anti-VEGF (after 3–4 injections) - Severe DME with thick retinal thickening - Proliferative disease (pan-retinal photocoagulation) - Intravitreal corticosteroids (triamcinolone) are second-line, used when anti-VEGF fails or is contraindicated ## Clinical Pearl: **Circinate exudates** (hard exudates in a ring around the macula) are a hallmark of DME and indicate lipid accumulation from increased vascular permeability—a VEGF-driven process. Anti-VEGF directly addresses this pathophysiology. ## Tip: Do NOT jump to pan-retinal photocoagulation (PRP) unless there is **proliferative disease** (neovascularization of disc or elsewhere, vitreous hemorrhage, or severe NPDR with high-risk features). This patient has NPDR only.